Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study.
Sign Up to like & getrecommendations! Published in 2023 at "European journal of endocrinology"
DOI: 10.1093/ejendo/lvac011
Abstract: OBJECTIVES Anaplastic thyroid carcinoma (ATC) has a poor survival. The combination of Dabrafenib plus Trametinib (DT) had a significant impact in survival of BRAF p.V600E patients. However, durable responses may be compromised by resistance. We… read more here.
Keywords: braf; therapy; target therapy; anaplastic thyroid ... See more keywords
BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC
Sign Up to like & getrecommendations! Published in 2021 at "Medicina"
DOI: 10.3390/medicina57121339
Abstract: Backgroundand objectives: Patients with BRAF-mutated metastatic colorectal cancer have considerably poorer responses to conventional systemic treatment. The real-world effects of triplet therapy with BRAF, mitogen-activated protein kinase kinase, and epidermal growth factor receptor inhibitors in… read more here.
Keywords: therapy; metastatic colorectal; braf mutated; therapy braf ... See more keywords